Beijing Daxing District four sets of leaders visited Beijing cell therapy Group investigation

Photo: Beijing Daxing District four sets of leaders investigation Beijing cell therapy Group

On December 25, four sets of leaders including Wang Youguo, secretary of the Daxing District Committee of Beijing, Liu Xueliang, deputy secretary of the District Committee and head of the People's Government, Jin Weidong, Secretary and director of the Party Leading Group of the Standing Committee of the National People's Congress, and Wu Wenping, Secretary and Chairman of the Party leading Group of the Beijing Daxing District Committee of the CPPCC, And Free Trade Zone leaders such as Deputy Secretary of the Party Working Committee and full-time deputy director of the Management Committee of Airport Economic Zone (Daxing) Luo Ming visited Beijing Cell Therapy Group for investigation and research. Dr. Ye Zhenlong, PRESIDENT of Beijing Cell Therapy Group received and accompanied him to visit the project of Beijing Cell Therapy Group (Phase I).

At the scene, Dr. Ye Zhenlong introduced the first phase project and the second phase planning of Beijing Cell Therapy Group to the leaders of the four sets of groups, and reported the latest progress and achievements of the group in the field of cell therapy. It is the only company in China that integrates "non-viral vector transfection, nano antibody and mRNA industrialization technology platform". It is also the first company that has been approved IND non-viral vector CAR-T cell therapy new drug in China. T cells secreted high-level nano antibodies for the first time in the world, and the drug efficacy of solid tumor cells was remarkable. Independent research and development of internationally leading brand new transposon enzyme system, the cost is only 1/10 of the viral system of non-viral BZ transposon, with complete intellectual property rights; Self-produced high-purity and high-activity nucleotides, reducing the cost of 90% and other key technological breakthroughs, from cell raw materials, solid tumor cell drug efficacy, cell drug cost, RNA synthesis raw materials, RNA delivery system to solve the CGT industry "bottleneck" problem. As of December 2021, Shanghai Cell Therapy Group has applied for 243 patents worldwide, covering China, the United States, Europe, Japan, Australia and other countries and regions.

Photo: Beijing Daxing District four sets of leaders investigation Beijing cell therapy Group

Beijing Cell Therapy Group (Phase I) project aims to build a cell storage center, a standardized regional center of the cell industry and a popular science exhibition window. With a total construction area of 10,000 square meters, the project integrates cell storage, cell drugs, gene testing, health management, medical services and other comprehensive cell health services into one. Including cell preservation center, cell production and preparation center and testing center, Baze Clinic and Baze Medical Beauty Center, customer reception service center, the cell preservation center design capacity of more than 80 storage tanks, the maximum cell sample storage capacity of more than 120,000 people. The Beijing Cell Therapy Group (Phase II) project, including the construction of an international R&D center and an international research hospital, will also be launched. The core of research hospitals is independent innovation. Beijing Cell Therapy Group helps the life and health industry to run the last mile by building an international cell science and technology center, an international nucleic acid science and technology center, and an open international research hospital. Adhere to the core technology breakthrough, to create greater value for customers.

Photo: Beijing Daxing District four sets of leaders investigation Beijing cell therapy Group

Four sets of group leader of group "crack the CGT industries' their 'problem", propel the development of the industry's leading achievements, especially the pai tse T cell immune drugs gave high praise of the progress made, to group adhere to independent research and development, to scientific and technological innovation, to the international standards of affirmative exploration spirit, The second phase of Beijing Cell Therapy Group and the realization of Baize plan are full of expectations.

Beijing Cell Therapy Group will continue to maintain the spirit of innovation and exploration, and join hands with airport to build the world's largest cell storage bank, research and development and production center and cell drug clinical trial hospital, leading the development of the CGT industry and jointly building a new development pattern.